Introduction
Tricuspid regurgitation (TR) is common in patients with structural heart disease. Trivial or mild TR is often an incidental finding on routine echocardiography, almost universally present in elderly patients and is generally regarded as benign. 1 The prevalence of moderate and severe TR increases with age and is often present in patients with concomitant left-sided valvular heart disease. 2 Significant (moderate and severe) TR may be asymptomatic for an extended period of time. However, left untreated, significant TR is associated with progressive right ventricular (RV) dilation and dysfunction, heart failure, and increased mortality. [3] [4] [5] The natural history of TR is not very well known and is confounded by the aetiology of TR (primary vs. secondary), presence of associated left-sided valvular heart disease and patients' haemodynamic profile. 6, 7 Factors influencing the development of TR from mild to significant have not been characterized, and the prognostic implications of a fast vs. a slow development of TR are not known. Accordingly, this study investigated the factors influencing the development from none or mild to significant TR in the largest cohort of patients so far referred for transthoracic echocardiography, and assessed the prognostic implications of fast development of significant TR.
Methods Patients
From the departmental echocardiographic database of the Leiden University Medical Center (Leiden, The Netherlands), patients with moderate to severe native TR were selected. The aetiology of TR was defined according to current recommendations [primary (organic) vs. secondary (functional)]. 8 Patients with prior tricuspid surgery (replacement or repair), active endocarditis, age < _18 years, and those with known congenital heart disease with involvement of the tricuspid valve were excluded. After identification of the index echocardiogram showing the first diagnosis of moderate or severe TR, a retrospective search was performed to identify the first echocardiogram with none or mild TR. In total, the first 1000 consecutive patients with an available echocardiogram at baseline (with none or mild TR) and a second (index) echocardiogram with significant (moderate or severe) TR performed between June 1991 and November 2015 were included in this analysis. The time elapsed between the first echocardiogram (with none or mild TR) and the index echocardiogram (with moderate or severe TR) was calculated. The patient population was divided into quartiles according to the time between the first and index echocardiogram. This analysis yielded four groups of patients with different rates of preceding progression to significant TR (Group 1: fastest, Group 2: fast, Group 3: slow, Group 4: slowest).
Demographics and clinical data were evaluated at the time of the first (baseline) and index echocardiogram. Clinical variables included cardiovascular risk factors, total cholesterol levels, haemoglobin level, and glomerular filtration rate calculated by the Modification of Diet in Renal Disease formula. 9 Body surface area was calculated with the Mosteller method. 10 Data were collected from the departmental Cardiology Information System (EPD-Vision V R ; Leiden University Medical Centre, Leiden, the Netherlands) and subsequently analysed retrospectively. The institutional review board of the Leiden University Medical Centre approved this retrospective analysis of clinically acquired data and waived the need for patient written informed consent.
Echocardiography
The transthoracic echocardiograms were performed at rest with commercially available ultrasound systems (System 5, Vivid 7 and E9 systems; GE-Vingmed, Horten, Norway) and images were digitally stored for offline analysis (EchoPAC version 113.0.3; GE-Vingmed, Horten, Norway). Data acquisition was performed systematically according to institutional clinical protocols. The first echocardiogram (with none or mild TR) and the index echocardiogram (with moderate or severe TR) were prospectively re-analysed by two of the authors (E.A.P and P.V.D.B). All echocardiographic variables in this report were measured from the original, digitalised echocardiographic data at both time points (first and index echocardiograms, n = 2000); data were not extracted from clinical reports. Parasternal, apical, and subcostal views were used to acquire two-dimensional (2D), colour, pulsed, and continuous-wave Doppler data. From the apical two-and four-chamber views, left ventricular (LV) ejection fraction was quantified using the Simpson's biplane method and expressed as percentage. 11 The LV mass was calculated from the 2D linear measurements obtained on the parasternal LV long-axis view as recommended. 11 Aortic valve haemodynamics and aortic valve area were assessed and, if present, aortic stenosis and regurgitation were graded according to current recommendations. 12 The severity of mitral regurgitation was qualitatively graded on colour flow Doppler. 8 Left ventricular diastolic dysfunction was assessed according to current recommendations. 13 Right ventricular dimensions (including basal, mid cavity, and longitudinal diameters) were measured according to current guidelines. 11 Significant tricuspid annular dilatation was defined by an end-diastolic diameter of >21 mm/m 2 (or >35 mm) on a RV focused four-chamber view. 8 End-diastolic RV sphericity index was calculated as RV mid diameter divided by the RV longitudinal diameter. 14 In addition, RV endsystolic and end-diastolic areas were traced on a focused RV apical view and RV fractional area change was calculated. Tricuspid annular plane systolic excursion (TAPSE) was calculated on M-mode recordings of the lateral tricuspid annulus in a RV focused apical view.
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Integrative assessment of TR severity was performed through a multiparametric approach (including jet size, jet eccentricity, and vena contracta) as recommended by recent guidelines. 15 Trace of TR was considered as no TR in the current analysis. Furthermore, quantitation of TR was performed using the proximal flow convergence method as previously validated. 16, 17 Tricuspid valve tenting height and area were measured at mid-systole. The aetiology of the TR was conventionally classified into primary/organic TR (entailing damage to the tricuspid valve) and secondary/functional TR (involving structurally normal leaflets, but with annular or RV dilatation, or RV dysfunction). Pacemaker (or implantable cardioverter defibrillator) lead-related TR was only classified as organic TR in the absence of any coexisting significant left-sided valvular heart disease (defined as > _moderate mitral regurgitation/stenosis or aortic stenosis/regurgitation) or LV myocardial disease (defined as LV ejection fraction < 50%). TR caused by endocarditis or congenital disease as organic causes were exclusion criteria for this analysis. Finally, isolated TR, a novel entity, which has been defined as TR occurring secondary to atrial fibrillation, 18 was classified as functional TR. Systolic pulmonary artery pressure was based on peak TR velocity jet and right atrial pressure. Right atrial pressure was estimated based on the inferior vena cava (IVC) diameter and phasic variation with breathing (IVC diameter < _21 mm with >50% inspiratory collapse: 3 mmHg; IVC diameter >21 mm with < _50% inspiratory collapse: 15 mmHg; intermediate situations: 8 mmHg).
Follow-up
All-cause mortality data were collected from the departmental cardiology information system or the Social Security Death Index and were complete for all patients. In addition, the occurrence and timing of any cardiac surgery [including coronary artery bypass grafting (CABG), aortic/mitral valve surgery and transcatheter therapy] were recorded. As per exclusion criteria, patients who underwent tricuspid valve surgery between the first and the index echocardiogram were not included in this analysis. In contrast, surgical interventions or transcatheter treatments other than tricuspid valve surgery were not excluded. The occurrence of tricuspid valve surgery (repair or replacement) after the index echocardiography was recorded.
Statistical analysis
All continuous variables followed a Gaussian distribution and accordingly are presented as mean ± standard deviation. Comparisons of continuous variables across the groups divided according to quartiles of time to development of significant TR were performed with one-way analysis of Development of significant TR and prognosis variance, and multiple comparisons for significant results were performed with Bonferroni correction. All categorical variables are presented as percentages and frequencies and were compared with the v 2 test. To investigate the independent correlates of TR development, a binary logistic regression model was performed with inclusion of all variables with a Pvalue <0.1 in univariable analysis. In addition, any intervening cardiac surgery (including CABG or left-sided valvular surgery) and transcatheter therapy occurring between the two echocardiograms were included in this analysis. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. The cumulative event rates were estimated with the Kaplan-Meier method and compared with the log-rank test. A multivariable Cox proportional hazards regression analysis was performed to investigate the independent associates of all-cause mortality at the time-point of significant TR. To assess the impact of time to development of significant TR, the interval between the two echocardiograms (in years) was included as a continuous variable. Furthermore, any CABG, left-sided cardiac surgery or any tricuspid surgery after the index echocardiography were included in the model as covariates. Hazard ratios (HRs) and 95% CI were calculated. A two-tailed P-value of <0.05 was considered significant. All statistical analyses were performed using SPSS for Windows version 23 (SPSS Inc.; Armonk, NY: IBM Corp).
Results

Baseline characteristics of the patients
Of the 1000 included patients, 290 patients (29%) did not have TR and 710 patients (71%) had mild TR at the time of the first (baseline) echocardiogram ( Figure 1A) . At the second (index) echocardiography, 810 patients (81%) had moderate TR, and 190 patients (19%) had severe TR ( Figure 1A) . The aetiology of TR is presented in Figure 1B : 5.8% of patients had primary/organic TR, and 94.2% had secondary/ functional TR. The population was divided into quartiles of time to development of significant TR (Group 1: < _1.2 years, n = 251; Group 2: 1.3-4.7 years, n = 248, Group 3: 4.8-8.9 years, n = 251; Group 4: > _9.0 years, n = 250). Supplementary material online, Tables S1 and S2 show the clinical and echocardiographic characteristics of the groups, respectively. Patients showing fastest TR development (Group 1) were older, more frequently female and showed a higher percentage of coexisting coronary artery disease, peripheral artery disease, renal disease, and lung disease. Furthermore, this group showed a higher intake of anti-platelet therapy, beta blockers and diuretics and had worse haemoglobin levels and kidney function. On baseline echocardiography, patients with fastest development to significant TR showed a higher percentage of significant left-sided valvular disease and right heart remodelling.
Determinants of tricuspid regurgitation development
Between the first and index echocardiogram, 222 patients underwent interventions for left-sided valvular heart disease and 46 patients underwent isolated CABG ( Figure 2) . As shown in Supplementary material online, Table S3 and Figure 3 , a binary logistic regression model was constructed to investigate the independent factors associated with fastest development of TR. Older age, presence of a pacemaker, or defibrillator lead, presence of mild TR vs. no TR at baseline, reduced RV systolic function and increased tricuspid annulus diameter were independently associated with fast progression of TR. Any left-sided valvular surgery performed between the first and the index echocardiogram was also associated with a higher risk of fast TR progression.
Prognostic impact of tricuspid regurgitation development
During a median follow-up of 2.9 years (interquartile range 1.3-5.5 years) after the index echocardiogram (with moderate or severe TR), 421 patients (42.1%) died. The mortality rate was similar among patients who developed severe TR as compared to patients who developed moderate TR (44.8% vs. 41.4%; log rank P = 0.211). During this period, 120 patients underwent cardiac surgery including CABG (n = 3), isolated left-sided valve intervention (n = 51) and tricuspid valvular repair (combined n = 60, isolated n = 6). Figure 4 shows that the cumulative event-free survival was significantly worse among patients with fastest development of significant TR (Group 1), compared with their counterparts (Kaplan-Meier estimated cumulative event rate of 49.4% for Group 1, 48.1% for Group 2, 46.1% for Group 3, and 34.0% for Group 4; log rank P < 0.001). Table 1 shows the association between time to development of significant TR and all-cause mortality. In unadjusted analysis, older age (HR 1.03, 95% CI 1.02-1.04), lower TAPSE (HR 1.05, 95% CI 1.03-1.07), lower LV ejection fraction (HR 1.02, 95% CI 1.01-1.02), higher RV systolic pressures (HR 1.02, 95% CI 1.01-1.02), and short term of significant TR development (HR 1.09, 95% CI 1.07-1.12) were significantly associated with all-cause mortality. The occurrence of CABG and left-sided valvular intervention after the index echocardiogram were not significantly associated with all-cause mortality. Although not statistically significant, tricuspid valve surgery occurring after the index echocardiogram demonstrated a trend towards a protective effect (HR 0.74, 95% CI 0.45-1.01).
By multivariable analysis, a faster development of significant TR increased all-cause mortality (HR per preceding year of TR progression 1.09, 95% CI 1.06-1.11), independent of age, TAPSE, LV ejection fraction and RV systolic pressure ( Table 1) .
Discussion
In the present large-scale contemporary population undergoing serial echocardiograms in whom significant TR developed, patients with fastest development of significant TR (< _1.2 years) were older, more frequently female and showed more RV dilation and dysfunction as compared to patients with slowest development of TR (> _9.0 years). Left-sided valve surgery without concomitant tricuspid surgery was also associated with a higher risk of fast TR progression. Importantly, in patients who developed significant TR, a fast development of significant TR was independently associated with all-cause mortality independent of age, LV ejection fraction, RV systolic pressure, and TAPSE.
Determinants of tricuspid regurgitation development
The risk factors for development of significant TR have been addressed in small studies with specific subpopulations. development occurred over a mean follow-up of 5.3 ± 2.9 years, and patients with TR development were significantly older, had more frequent coronary artery disease, permanent atrial fibrillation, and heart failure. 6 The independent associates of TR development included increase in pulmonary artery pressures, permanent atrial fibrillation and coronary artery disease with mainly preserved LV ejection fraction. 6 In 88 patients with pulmonary hypertension and functional TR, Medvedofsky et al. 7 reported various patterns of TR evolution:
TR progression, n = 35; stable TR, n = 36 and TR regression, n = 17. Worsening of pulmonary hypertension, increase of RV sphericity, tricuspid annular dilatation, and increased TV tenting area were independently associated with TR progression. 7 Finally, in the Framingham Heart Study, longitudinal echocardiography data showed that the determinants of significant TR were age (OR 1.5/ 9.9 years; 95% CI 1.3-1.7), body mass index (OR 0.7/4.3 kg/m 2 ; 95% CI 0.6-0.8), and female sex (OR 1.2, 95% CI 1.0-1.6). 2 By including a much larger population, this study provides novel insights into the development of TR. In our series, older age, presence of a pacemaker or defibrillator lead, presence of mild (vs. absent) TR at baseline, reduced RV systolic function, increased tricuspid annulus diameter, and the performance of left-sided valvular surgery without concomitant tricuspid valve annuloplasty were independently associated with fast development of TR. These findings support current guidelines recommending tricuspid annuloplasty during leftsided valvular surgery for patients with at least moderate functional TR and/or tricuspid annulus dilatation. 12 Moreover, with the introduction of novel transcatheter valve therapies, 19, 20 earlier intervention in patients with TR can be considered.
Prognostic influence of development of tricuspid regurgitation
The prognostic implications of moderate and severe TR were shown by Nath et al. 3 in a large study encompassing more than 5200
patients. During follow-up of more than 5 years, both moderate and severe TR were associated with worse outcome, after stratifying the population according to pulmonary pressures or LV or RV size and function, whereas a mild or lesser degree of TR did not affect outcome. 3 Similarly, Koelling et al. 4 reported that moderate and severe TR were associated with poor outcomes in 1421 patients with reduced LV function. Furthermore, after mitral valve surgery, [21] [22] [23] transcatheter mitral valve repair, 24 aortic valve surgery, 25 and aortic valve transcatheter replacement, 26 the incidence of significant TR increases over time and has a deleterious effect on prognosis.
Whereas the association between moderate and severe TR and poor prognosis is well established, the prognostic importance of the development from mild to significant TR has not been elucidated. Our study is the first to show that the time to develop a significant degree of TR impacts prognosis independent from other known prognosticators (with a 9% decrease in mortality per preceding year of development). These results may promote the clinical relevance of early identification of patients with risk factors for faster development of TR as close surveillance may be needed to provide appropriate therapy to reduce the impact of moderate and severe TR on outcomes. Furthermore, given the high mortality associated with isolated surgical tricuspid valve interventions 27 or reoperation, 28,29 the advent of novel transcatheter therapies for moderate or severe TR may offer a lesser invasive and safer alternative for earlier treatment. Current estimates indicate that only 8000 patients per year are referred for isolated tricuspid valve surgery which contrasts sharply with the estimated prevalence of 1.6 million patients with significant TR in the United States. 30 Therefore, there is a clear clinical unmet need for better treatment of patients with severe TR. Experience with novel transcatheter therapies for TR is accumulating, and several ongoing trials will provide further evidence on the feasibility, safety and durability of these treatments.
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Study limitations
The present evaluation has limitations inherent to its retrospective design. Serial echocardiograms were not obtained at fixed intervals. Development of significant TR and prognosis circumstances that indicated performance of the second echocardiogram. Patients without symptoms may have had a delay in diagnosis of the severity of TR, whereas in patients with clinical symptoms the diagnosis of significant TR may have been established earlier.
However, in sensitivity analysis with a random sample of 200 patients (100 with slow progression and 100 with fast progression), the clinical reasons for ordering the index echocardiogram and the number of echocardiograms performed between both time points were not different (analysis not shown). In both groups, the main clinical setting in which the index echocardiogram was performed in the outpatient clinic (65% in slow progression of TR and 58% in fast progression of TR) and the time interval of echocardiographic follow-up prior to development of significant TR were comparable (562 vs. 504 days in slow and fast progression of TR, respectively). Notwithstanding, a longitudinal, prospective analysis with serial echocardiograms at regular intervals would provide a more accurate estimate of the frequency and rate of TR progression. Furthermore, survivorship bias may also be present since, by study design, all patients survived during the development period of significant TR. As the exact cause of death could not be specified in all cases, all-cause mortality was chosen as primary endpoint. All echocardiographic evaluations were performed with 2D echocardiography; 3D echocardiography may have provided more insights in the complex interaction between RV and the tricuspid valve apparatus. Finally, by protocol design, all patients in our study had progression from no/mild to moderate/severe TR (although at different rates). Future large-scale studies are underway to determine the incidence and predictors of any TR progression (vs. no progression) over time.
Conclusions
In the present large clinical series of patients with progressive TR, fast development of TR was associated with older age, presence of a pacemaker or defibrillator lead, presence of mild (vs. no) TR, echocardiographic signs of RV dilation and dysfunction, and left-sided valve surgery without concomitant tricuspid surgery. Importantly, a shorter time to develop significant TR was strongly associated with all-cause mortality, independent of age, LV ejection fraction, RV systolic pressure, and TAPSE.
Supplementary material
Supplementary material is available at European Heart Journal online.
